Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCR-036
- Development stage
- Preclinical
- Lead developer
- Vicero Bio
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
VCR-036 is a novel pentavalent, bispecific immunotherapy targeting both PD-1 and CTLA-4. It is being developed by Vicero for the treatment of cancer. The drug leverages proprietary VINCOBODY technology, which utilizes single monomeric variable domains (VHHs) to create highly potent and stable molecules capable of engaging multiple immune checkpoint targets with high affinity and avidity. This next-generation approach aims to enhance the body’s natural immune response against tumors while offering improved tissue penetration, stability under diverse conditions, and a convenient six-week subcutaneous dosing schedule. Preclinical studies have demonstrated robust efficacy and safety profiles for VCR-036[1][2]. The therapy is currently in preclinical development.
- Other names
- VINCOBODY
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on VCR-036.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCR-036.